159 related articles for article (PubMed ID: 32234526)
1. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response.
Sahu B; Narota A; Naura AS
Eur J Pharmacol; 2020 Jun; 877():173091. PubMed ID: 32234526
[TBL] [Abstract][Full Text] [Related]
2. Two hit induced acute lung injury impairs cognitive function in mice: A potential model to study cross talk between lung and brain.
Sahu B; Sandhir R; Naura AS
Brain Behav Immun; 2018 Oct; 73():633-642. PubMed ID: 30026058
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.
Liu W; Ren X; Wang Q; Zhang Y; Du J
Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):159-167. PubMed ID: 32865668
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
Kapoor K; Singla E; Sahu B; Naura AS
Mol Cell Biochem; 2015 Feb; 400(1-2):153-62. PubMed ID: 25404465
[TBL] [Abstract][Full Text] [Related]
5. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
Dharwal V; Naura AS
Biochem Pharmacol; 2018 Apr; 150():24-34. PubMed ID: 29355504
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
Ghonim MA; Pyakurel K; Ibba SV; Al-Khami AA; Wang J; Rodriguez P; Rady HF; El-Bahrawy AH; Lammi MR; Mansy MS; Al-Ghareeb K; Ramsay A; Ochoa A; Naura AS; Boulares AH
J Transl Med; 2015 Jul; 13():225. PubMed ID: 26169874
[TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate prevents acute lung injury related cognitive impairment potentially via reducing inflammation.
Wang X; Wang Y; Pan H; Yan C
J Cardiothorac Surg; 2021 Nov; 16(1):331. PubMed ID: 34772431
[TBL] [Abstract][Full Text] [Related]
8. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Ahmad A; Vieira JC; de Mello AH; de Lima TM; Ariga SK; Barbeiro DF; Barbeiro HV; Szczesny B; Törö G; Druzhyna N; Randi EB; Marcatti M; Toliver-Kinsky T; Kiss A; Liaudet L; Salomao R; Soriano FG; Szabo C
Pharmacol Res; 2019 Jul; 145():104263. PubMed ID: 31071432
[TBL] [Abstract][Full Text] [Related]
9. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
11. Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis.
Ahmad A; Haas De Mello A; Szczesny B; Törö G; Marcatti M; Druzhyna N; Liaudet L; Tarantini S; Salomao R; Garcia Soriano F; Szabo C
Shock; 2020 May; 53(5):653-665. PubMed ID: 31274831
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice.
Sethi GS; Sharma S; Naura AS
IUBMB Life; 2019 Jul; 71(7):1003-1013. PubMed ID: 30964965
[TBL] [Abstract][Full Text] [Related]
13. Poly-(ADP-ribose) polymerases inhibition by olaparib attenuates activities of the NLRP3 inflammasome and of NF-κB in THP-1 monocytes.
Mustafa K; Han Y; He D; Wang Y; Niu N; Jose PA; Jiang Y; Kopp JB; Lee H; Qu P
PLoS One; 2024; 19(2):e0295837. PubMed ID: 38335214
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
15. Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.
Kovács D; Vántus VB; Vámos E; Kálmán N; Schicho R; Gallyas F; Radnai B
Oxid Med Cell Longev; 2021; 2021():7308897. PubMed ID: 34567413
[TBL] [Abstract][Full Text] [Related]
16. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.
Ahmad A; Olah G; Herndon DN; Szabo C
Br J Pharmacol; 2018 Jan; 175(2):232-245. PubMed ID: 28146604
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1α, Nrf2, and NFκB.
Kovacs K; Vaczy A; Fekete K; Kovari P; Atlasz T; Reglodi D; Gabriel R; Gallyas F; Sumegi B
Invest Ophthalmol Vis Sci; 2019 Apr; 60(5):1478-1490. PubMed ID: 30973576
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia.
Teng F; Zhu L; Su J; Zhang X; Li N; Nie Z; Jin L
Neurochem Res; 2016 Jul; 41(7):1516-26. PubMed ID: 26869042
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
